medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 2

<< Back Next >>

Ann Hepatol 2017; 16 (2)

High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population

Gonzalez-Aldaco K, Panduro A, Rebello PJR, Martinez-Lopez E, Gleyzer K, Fierro NA, Roman S

Language: English
References: 50
Page: 221-229
PDF size: 319.03 Kb.


ABSTRACT

Background. The prevalence of two functional polymorphisms (rs1127354 and rs7270101) of the inosine triphosphatase (ITPA) gene associated with ribavirin-induced hemolytic anemia (RIHA) during antiviral therapy for hepatitis C virus (HCV) infection varies by ethnicity. In Mexico, the distribution of these polymorphisms among Native Amerindians (NA) and admixed population (Mestizos) is unknown. This study aimed to determine the prevalence of the ITPA polymorphisms among healthy NA and Mestizos, as well as in HCV patients from West Mexico. Material and methods. In a cross-sectional study, 600 unrelated subjects (322 Mestizos, 100 NA, and 178 treatment-naïve, HCV-infected Mestizos patients) were enrolled. A medical history was registered. ITPA genotype was determined by Real-Time PCR. Fst-values and genetic relatedness between study and reference populations were assessed. Results. The frequency of the risk genotypes rs1127354CC and rs7270101AA was higher among NA (98-100%) than in Mestizos (87-92.9%), (p ‹ 0.05). The NA presented the highest prevalence of the rs1127354CC genotype reported worldwide. The Fst-values revealed a genetic relatedness among Mexican NA, South Americans and African populations (p › 0.05). The frequency of the predicted risk for RIHA was higher among NA (98%) than in Mestizos (80.5%) and HCV-infected patients (81.5%) (p ‹ 0 .01). The CC/AA alleles were associated with lower values of total bilirubin, aspartate/alanine aminotransferases, and aspartate-to-platelet- ratio-index score among HCV-patients. Conclusion. A high prevalence of the ITPA polymorphisms associated with RIHA was found in Mexican NA. These polymorphisms could be a useful tool for evaluating potential adverse effects and the risk or benefit of antiviral therapy in Mexicans and other admixed populations.


REFERENCES

  1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.

  2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-29.

  3. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-68.

  4. Feld JJ. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Pract Res Clin Gastroenterol 2012; 26: 429-44.

  5. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 257-64.

  6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54, 1433-44.

  7. Chang TW, Heel RC. Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs 1981; 22, 111-28.

  8. Jain MK, Zoellner C. Role of ribavirin in HCV treatment response: now and in the future. Expert Opin Pharmacother 2010; 11: 673-83.

  9. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowle- Bakre M, Rees DC, Thein SL, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111: 360-7.

  10. Sakumi K, Abolhassani N, Behmanesh M, Iyama T, Tsuchimoto D, Nakabeppu Y. ITPA protein, an enzyme that eliminates deaminated purine nucleoside triphosphates in cells. Mutat Res 2010; 703: 43-50.

  11. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-8.

  12. Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, Mc- Caughan GW, Crawford DH, et al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology 2014; 59: 2152-60.

  13. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.

  14. Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 2014; 49: 579-81.

  15. Trinks J, Hulaniuk ML, Caputo M, Pratx LB, Re V, Fortuny L, Pontoriero A, et al. Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Pharmacogenomics J 2014; 14: 549-54.

  16. Martinez-Cortes G, Salazar-Flores J, Fernandez-Rodriguez LG, Rubi-Castellanos R, Rodriguez-Loya C, Velarde-Felix JS, Muñoz-Valle JF, et al. Admixture and population structure in Mexican-Mestizos based on paternal lineages. J Hum Genet 2012; 57: 568-74.

  17. Ruiz-Linares A, Adhikari K, Acuna-Alonzo V, Quinto- Sanchez M, Jaramillo C, Arias W, Fuentes M, et al. Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet 2014; 10, e1004572.

  18. INEGI. Instituto Nacional de Estadística y Geografía. Censo Nacional 2010. Available at: http://www.inegi.org.mx/. Accessed: January 04 2016.

  19. Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, Trujillo- Trujillo ME, Roman S, Trujillo-Ochoa JL, Panduro A. Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients. Mem Inst Oswaldo Cruz 2015; 110: 267-71.

  20. Roman S, Jose-Abrego A, Fierro NA, Escobedo-Melendez G, Ojeda-Granados C, Martinez-Lopez E, Panduro A. Hepatitis B virus infection in Latin America: a genomic medicine approach. World J Gastroenterol 2014; 20: 7181-96.

  21. Aceves D, Ruiz B, Nuno P, Roman S, Zepeda E, Panduro A. Heterogeneity of apolipoprotein E polymorphism in different Mexican populations. Hum Biol 2006; 78: 65-75.

  22. Roman S, Zepeda-Carrillo EA, Moreno-Luna LE, Panduro A. Alcoholism and liver disease in Mexico: genetic and environmental factors. World J Gastroenterol 2013; 19: 7972-82.

  23. Ramos-Lopez O, Roman S, Martinez-Lopez E, Gonzalez-Aldaco K, Ojeda-Granados C, Sepulveda-Villegas M, Panduro A. Association of a novel TAS2R38 haplotype with alcohol intake among Mexican-Mestizo population. Ann Hepatol 2015; 14: 729-34.

  24. Vergara M, Bejarano G, Dalmau B, Gil M, Miquel M, Sanchez- Delgado J, Casas M, et al. Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2015; 27: 826-33.

  25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

  26. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban T J, et al. Variants in the ITPA gene protect against ribavirin- induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139: 1181-9.

  27. Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 2015; 1: 47-50.

  28. 1000 genomes project. Available at: http:// www.1000genomes.org/. Accessed: October 7, 2015.

  29. Martinez-Cortes G, Salazar-Flores J, Haro-Guerrero J, Rubi- Castellanos R, Velarde-Felix JS, Munoz-Valle JF, Lopez- Casamichana M, et al. Maternal admixture and population structure in Mexican-Mestizos based on mtDNA haplogroups. Am J Phys Anthropol 2013; 151: 526-37.

  30. Schurr TG, Sherry ST. Mitochondrial DNA and Y chromosome diversity and the peopling of the Americas: evolutionary and demographic evidence. Am J Hum Biol 2004; 16: 420-39.

  31. Tamm E, Kivisild T, Reidla M, Metspalu M, Smith DG, Mulligan CJ, Bravi CM, et al. Beringian standstill and spread of Native American founders. PLoS One 2007; 2: e829.

  32. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006; 52(2): 240-7.

  33. Marinaki AM, Duley JA, Arenas M, Ansari A, Sumi S, Lewis CM, Shobowale-Bakre M, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 2004; 23(8-9): 1393-7.

  34. Panduro A, Escobedo Melendez G, Fierro NA, Ruiz Madrigal B, Zepeda-Carrillo EA, Roman S. [Epidemiology of viral hepatitis in Mexico]. Salud Publica Mex 2011; 53(Suppl. 1): S37-45.

  35. Lin S, McLennan AG, Ying K, Wang Z, Gu S, Jin H. Wu C, et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene. J Biol Chem 2001; 276: 18695-701.

  36. Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs MM, Bandyopadhyay S, McCaffrey AP, et al. Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 2010; 52: 1897-905.

  37. Corral-Jara KF, Trujillo-Ochoa JL, Realpe M, Panduro A, Roman S, Fierro NA. Rethinking the immune properties of bilirubin in viral hepatitis: from bench to bedside. Clin Transl Immunology 2015; 4, e54.

  38. Zhu Z, Wilson AT, Mathahs MM, Wen F, Brown KE, Luxon BA, Schmidt WN. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008; 48, 1430-9.

  39. Barrett S, Kieran N, Ryan E, O’Keane JC, Crowe J. Intrahepatic hepatitis C viral RNA status of serum polymerase chain reaction-negative individuals with histological changes on liver biopsy. Hepatology 2001; 33: 1496-502.

  40. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.

  41. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.

  42. Gonzalez-Aldaco K, Rebello Pinho JR, Roman S, Gleyzer K, Fierro NA, Oyakawa L, Ramos-Lopez O, et al. Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. PLoS One 2016; 11: e0146258.

  43. http://www.cibic.com.ar/laboratorios-bioquimicos/polimorfismos- en-el-gen-de-la-itpa-asociados-a-anemia-por-ribavirina- utilizada-en-el-tratamiento-de-la-hepatitis-c-cronica/ Accessed on March 8, 2016.

  44. http://www. einstein. br/exames/exames/paginas/exame.aspx?CodExame=20122& Unidade=HIAE. Accessed on March 8, 2016.

  45. Cariani, E, Villa E, Rota C, Critelli, Trenti T. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. Clin Chem Lab Med 2011; 49, 1247-56.

  46. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; 8: 1221-8.

  47. Azimi F, Esmaeilzadeh A, Ramazani A. Clinical significance of ITPA rs67002563 polymorphism in patients with acute lymphoblastic leukemia treated with 6-mercaptopurine. Pharmacol Res 2015; 102: 61-2.

  48. Odahara S, Uchiyama K, Kubota T, Ito Z, Takami S, Kobayashi H, Saito K, et al. A Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD). PLoS One 2015; 10: e0137798.

  49. Xiong H, Xin HW, Wu XC, Li Q, Xiong L, Yu AR. Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients. Fundam Clin Pharmacol 2010; 24: 393-400.

  50. Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Fun E, Schalaak J, et al. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol 2012; 84: 1106-14.




2020     |     www.medigraphic.com